18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma

Abstract Background Immune checkpoint blockade such as ipilimumab and anti-PD1 monoclonal antibodies have significantly improved survival in advanced melanoma. Biomarkers are urgently needed as a majority of patients do not respond, despite treatment-related toxicities. We analysed pre-treatment 18F...

Full description

Bibliographic Details
Main Authors: Annie Wong, Jason Callahan, Marleen Keyaerts, Bart Neyns, Johanna Mangana, Susanne Aberle, Alan Herschtal, Sonia Fullerton, Donna Milne, Amir Iravani, Grant A. McArthur, Rodney J. Hicks
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Cancer Imaging
Subjects:
Melanoma
Immune checkpoint blockade
Biomarker
Positron emission tomography
Spleen to liver ratio
Online Access:http://link.springer.com/article/10.1186/s40644-020-00313-2

Internet

http://link.springer.com/article/10.1186/s40644-020-00313-2

Similar Items